Neurodegenerative Disease Therapeutics Market
完整報告名稱與涵蓋範圍
Neurodegenerative Disease Therapeutics Market Size, Share & Trends Analysis Report, By Indication (Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease and Other Rare Neurodegenerative Diseases, Multiple System Atrophy and Related Disorders), By Drug Modality (Small Molecules, Monoclonal Antibodies, Antisense Oligonucleotides and siRNA, Gene and Cell Therapies), By Mechanism (Symptomatic Therapies, Disease-Modifying Therapies), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The neurodegenerative disease therapeutics market covers medicines for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and related disorders, spanning symptomatic treatments and disease-modifying therapies across small molecules, antibodies, oligonucleotides and genetic and cell therapies. Diagnostics, neurostimulation devices and dementia care services are excluded, although biomarker-driven diagnosis is modelled as an adoption driver.
Anti-amyloid antibodies established the first disease-modifying category in Alzheimer's disease and are now being followed by subcutaneous formulations, tau-targeted agents and prevention trials in presymptomatic populations. In Parkinson's disease, continuous subcutaneous levodopa delivery, alpha-synuclein antibodies, LRRK2 inhibitors and dopaminergic cell replacement therapies are progressing, while ALS has seen the first genetically targeted antisense approval and an active pipeline of oligonucleotide and small-molecule candidates. Blood biomarkers, PET imaging capacity and infusion infrastructure govern the pace of uptake, and payers scrutinise the cost-effectiveness of chronic high-cost therapies with modest clinical effect sizes.
North America, Japan and Europe generate most revenue, with China widening reimbursement for novel neurology agents. Competition is concentrated among a few neuroscience leaders, complemented by biotechnology companies specialising in genetic medicine and cell therapy.
The InsightAce study supplies US$ forecasts for all indication, drug modality, mechanism and distribution channel and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neurodegenerative Disease Therapeutics Market Snapshot
Chapter 4. Global Neurodegenerative Disease Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Indication Estimates & Trend Analysis
5.1. Indication & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
5.2.1. Alzheimer's Disease
5.2.2. Parkinson's Disease
5.2.3. Amyotrophic Lateral Sclerosis
5.2.4. Huntington's Disease and Other Rare Neurodegenerative Diseases
5.2.5. Multiple System Atrophy and Related Disorders
Chapter 6. Market Segmentation 2: By Drug Modality Estimates & Trend Analysis
6.1. Drug Modality & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Modality:
6.2.1. Small Molecules
6.2.2. Monoclonal Antibodies
6.2.3. Antisense Oligonucleotides and siRNA
6.2.4. Gene and Cell Therapies
Chapter 7. Market Segmentation 3: By Mechanism Estimates & Trend Analysis
7.1. Mechanism & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Mechanism:
7.2.1. Symptomatic Therapies
7.2.2. Disease-Modifying Therapies
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital and Infusion Center Pharmacies
8.2.2. Retail and Specialty Pharmacies
Chapter 9. Neurodegenerative Disease Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Eli Lilly and Company
11.2. Eisai Co., Ltd.
11.3. Biogen Inc.
11.4. Roche Holding AG
11.5. Novartis AG
11.6. AbbVie Inc.
11.7. Ionis Pharmaceuticals, Inc.
11.8. Bayer AG (BlueRock Therapeutics)
11.9. Prothena Corporation plc
11.10. Denali Therapeutics Inc.
11.11. uniQure N.V.
11.12. Amylyx Pharmaceuticals, Inc.
11.13. Alector, Inc.
11.14. Sumitomo Pharma Co., Ltd.
11.15. Cerevance, Inc.
圖表清單 List of Tables & Figures
Table 1. Global Neurodegenerative Disease Therapeutics Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 1. Global Neurodegenerative Disease Therapeutics Market Segmentation Overview
Table 2. Global Neurodegenerative Disease Therapeutics Market Revenue Forecast by Drug Modality, 2026-2035 (US$ Mn)
Figure 2. Global Neurodegenerative Disease Therapeutics Market Share by Indication, 2026 & 2035
Table 3. Global Neurodegenerative Disease Therapeutics Market Revenue Forecast by Mechanism, 2026-2035 (US$ Mn)
Figure 3. Disease-Modifying Pipeline Across Alzheimer's, Parkinson's, ALS and Huntington's Disease
Table 4. Global Neurodegenerative Disease Therapeutics Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Global Neurodegenerative Disease Therapeutics Market Share by Drug Modality, 2026 & 2035
Table 5. North America Neurodegenerative Disease Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Diagnostic Infrastructure and Biomarker Availability as Gates to Therapy Uptake
Table 6. Europe Neurodegenerative Disease Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Neurodegenerative Disease Therapeutics Growth Opportunity Analysis
Table 7. Asia Pacific Neurodegenerative Disease Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Cell and Gene Therapy Programs in Neurodegeneration by Stage and Sponsor
Table 8. Latin America Neurodegenerative Disease Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Neurodegenerative Disease Therapeutics Market Participants
Table 9. Middle East & Africa Neurodegenerative Disease Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們